AMSBIO, a specialist supplier of high purity reagents for glycobiology and
regenerative medicine, has announced the launch of a new, highly purified
Chondroitinase ABC. This new enzyme is supplied protease-free, carrier-free and
with low-endotoxin levels for use in neuroscience and regenerative medicine
research.
Chondroitin Sulfate Proteoglycans (CSPGs) are involved in the inhibition of
axon regeneration after various forms of damage to the Central Nervous System,
including stroke or spinal cord injury. The enzyme Chondroitinase ABC purified
from Proteus vulgaris,
degrades these CSPGs, and has been shown to promote functional recovery and
neural regeneration.
AMSBIO’s new Chondroitinase ABC is a direct replacement for the protease-free
Chondroitinase ABC formerly supplied by Seikagaku Biobusiness Corporation (and
available through AMSBIO), which was discontinued by the manufacturer in 2011
as part of their broader decision to pull out of the research reagents and
glycobiology biochemicals business.
No comments:
Post a Comment